Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Abstract

Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ∼30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Among patients for whom R-CHOP therapy fails, 20% suffer from primary refractory disease (progress during or right after treatment) whereas 30% relapse after achieving complete remission (CR). Currently, there is no good definition enabling us to identify these 2 groups upon diagnosis. Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture. New strategies are currently being explored to obtain better CR rates and fewer relapses. Although young relapsing patients are treated with high-dose therapy followed by autologous transplant, there is an unmet need for better salvage regimens in this setting. To prevent relapse, maintenance therapy with immunomodulatory agents such as lenalidomide is currently undergoing investigation. New drugs will most likely be introduced over the next few years and will probably be different for relapsing and refractory patients.

Conflict of interest statement

Conflict-of-interest disclosure: B.C. is on the board of directors or an advisory committee for Celgene, Celltrion, MorphoSys, and Pfizer and has consulted for Gilead and Novartis. C.S. declares no competing financial interests.

© 2016 by The American Society of Hematology. All rights reserved.

Figures

Figure 1.

Outcome of patients with DLBCL after R-CHOP chemotherapy.

Figure 2.

Suggested algorithm for therapy in patients for whom R-CHOP therapy failed.